FDA's Overreach on Compounded Peptides Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Peptides may soon be easier to get amid RFK Jr.'s push, but experts warn of risks